{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:17:22Z","timestamp":1778872642000,"version":"3.51.4"},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":2451,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:p>Cinacalcet is the first calcimimetic drug approved by the United States Food and Drug Administration for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. A literature search, performed by using PubMed and MEDLINE from January 1997\u2013June 2004, identified articles concerning the efficacy and safety of cinacalcet in this patient population. Currently, Vitamin D and its analogs are considered first\u2010line therapy for secondary hyperparathyroidism. However, use of these agents is often accompanied by an increase in serum calcium and phosphorus concentrations, a problem that often limits their use. Cinacalcet's mechanism of action decreases parathyroid hormone, calcium, and phosphorus levels, offering potential advantages over the other treatments for secondary hyperparathyroidism. Additional clinical trials are needed to evaluate the long\u2010term safety and efficacy of the drug as a first\u2010line agent.<\/jats:p>","DOI":"10.1592\/phco.25.5.709.63595","type":"journal-article","created":{"date-parts":[[2005,6,14]],"date-time":"2005-06-14T04:43:46Z","timestamp":1118724226000},"page":"709-716","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cinacalcet: A New Treatment for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis"],"prefix":"10.1002","volume":"25","author":[{"given":"Cecelia A.","family":"Byrnes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian M.","family":"Shepler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2002.33401"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.07304.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000133041.27682.A2"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000073945"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(00)70064-3"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v31.pm9531176"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.7.1014"},{"issue":"3","key":"e_1_2_1_9_2","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation.","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(97)90352-8"},{"key":"e_1_2_1_11_2","volume-title":"Sensipar (cinacalcet HCl) tablets product information","author":"Amgen Inc.","year":"2004"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman WG","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00720.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000050224.03126.AD"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031633"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.057273"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.2.204"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02088.x"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.08.029"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.000604"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00183.x"},{"key":"e_1_2_1_22_2","first-page":"463A","article-title":"Long\u2010term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl [abstr]","volume":"14","author":"Moe SM","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_1_23_2","unstructured":"Amgen Inc.Sensipar (cinacalcet HCl) tablets Web site 2004. Available fromwww.sensipar.com. AccessedJune 22 2004."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.25.5.709.63595","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.25.5.709.63595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:01:32Z","timestamp":1761069692000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.25.5.709.63595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1592\/phco.25.5.709.63595"],"URL":"https:\/\/doi.org\/10.1592\/phco.25.5.709.63595","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}